UNSPSC 51273003: Dexivacaine

This classification denotes an anesthetic agent with the molecular formula C15H22N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QI846AL4NC, chemically known as 2-piperidinecarboxamide, n-(2,6-dimethylphenyl)-1-methyl-, (s)- but generally known as dexivacaine, which bears US NIH Compound Identifier 3032799. European Medicines Agency schedules Dexivacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07033MIG.

UNSPSC 51273003 Dexivacaine is a Commodity code that identifies a specific local anesthetic pharmaceutical; however, recent state and local solicitations tagged under this code do not procure dexivacaine itself but rather naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through cooperative purchasing and direct-to-manufacturer prescription programs. State and local buyers using this code span county health departments, state health and human services commissions, and multistate purchasing alliances. The mismatch between the code's nominal scope and the actual procurement activity suggests limited relevant recent demand for dexivacaine specifically under this UNSPSC classification in state and local markets.

Geographic activity appears concentrated in the Southeast and Upper Midwest, with documented solicitations from Seminole County, Florida; Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (serving Minnesota, Oregon, and other participating jurisdictions). Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities; and the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) for generic pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026. The code shows minimal recent activity specifically aligned to dexivacaine procurement and warrants monitoring for future solicitations if state and local demand for this anesthetic materializes.